Reference drugs for triple combination test drug in Russia [Design Issues]

posted by Yura – Belarus, 2019-11-19 21:51 (335 d 09:07 ago) – Posting: # 20830
Views: 2,932

(edited by mittyri on 2019-11-19 22:50)

Hi Beholder,
There is no reason for the regulator not to want to check section 4.5 of the Guideline on clinical development of fixed combination medicinal products :|>
Kind regards,

Edit: Guideline linked. Also changed the name in signature to the usual one[Mittyri]

Complete thread:

 Admin contact
21,164 posts in 4,410 threads, 1,476 registered users;
online 4 (1 registered, 3 guests [including 3 identified bots]).
Forum time: Tuesday 07:59 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz